期刊文献+

危重心衰稀释性低钠血症的机制及治疗策略 被引量:8

原文传递
导出
摘要 长期和失代偿心力衰竭患者经常有不同程度的水钠潴留症状,因慢性心衰导致神经一内分泌系统和肾脏水调节功能低下引起的稀释性低钠血症,既是心衰预后不良的一个重要因素,也是比较难处理的临床问题。
出处 《中华急诊医学杂志》 CAS CSCD 北大核心 2012年第1期97-100,共4页 Chinese Journal of Emergency Medicine
  • 相关文献

参考文献25

  • 1马爱群,胡大一主编..心血管病学[M].北京:人民卫生出版社,2005:878.
  • 2Douglas P,Peter Libby,RoberO,et al.心脏病学[M].陈灏珠主译.北京:人民卫生出版社,2007:483-565. 被引量:2
  • 3Goldsmith SR.Treatment options for hyponatremia in heart failure[J].Heart Fail Rev,2009,14 (2):65-73. 被引量:1
  • 4姚泰..生理学[M],2005.
  • 5孙宁玲编著..高血压治疗学[M].北京:人民卫生出版社,2009:1028.
  • 6Goldmlith SR. The role of vasopressin in congestive heart failure[J]. Cleve Clin J Med,2006,73 Suppl 3:S19-23. 被引量:1
  • 7陈主初主编..病理生理学[M].北京:人民卫生出版社,2005:423.
  • 8Frederic S. Bongard Darryl Y. Sue.现代重症监护诊断与治疗[M].北京:人民卫生出版社.2006.201. 被引量:3
  • 9黄震华.伴有低钠血症的心力衰竭的治疗进展[J].中国新药与临床杂志,2008,27(5):384-387. 被引量:13
  • 10Kazory A.Hyponatremia in heart failure:revisiting patho-physiology and therapeutic strategies[J].Clin Cardiol,2010,33 (6):322-329. 被引量:1

二级参考文献20

  • 1OREN RM. Hyponatremia in congestive heart failure[J]. Am J Cardiol, 2005, 95(9A) : 2B-7B. 被引量:1
  • 2ADROGUE HJ, MADIAS NE. Hyponatremia[J]. N Engl J Med, 2000, 342(21) : 1581-1589. 被引量:1
  • 3LEE CR, WATKINS ML, PATTERSON JH, et al. Vasopressin:a new target for the treatment of heart failure[J]. Am Heart J, 2003, 146(1): 9-18. 被引量:1
  • 4CHEN MC, CHANG HW, CHENG CI, et al. Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy[J]. Cardiology, 2003, 100(3): 136-142. 被引量:1
  • 5GOLDSMITH SR. Current treatment and novel pharmacologic treatments for hyponatremia in congestive heart failure[J]. Am J Cardiol, 2005, 95(9A): 14B-23B. 被引量:1
  • 6LICATA G, DI PASQUALE P, PARRINELLO G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects[J]. Am Heart J, 2003, 145(3): 459-466. 被引量:1
  • 7HIRANO T, YAMAMURA Y, NAKAMURA S, et al. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats[J]. J Pharmacol Exp Ther, 2000, 292(1): 288-294. 被引量:1
  • 8CHATTERJEE K, Neurohormonal activation in congestive heart failure and the role of vasopressin[J]. Am J Cardiol, 2005, 95 (9A) : 8B-13B. 被引量:1
  • 9THIBONNIER M. Vasopressin receptor antagonists in heart failure [J]. Curr Opin Pharmacol, 2003, 3(6) : 683-687. 被引量:1
  • 10GHEORGHIADE M, NIAZI I, OUYANG J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial[J]. Circulation, 2003, 107(21): 2690-2696. 被引量:1

共引文献17

同被引文献83

  • 1贺东风,方艳伟,刘力强,焦保华.脑外伤类型与低钠血症的发生和预后的关系研究[J].脑与神经疾病杂志,2011,19(5):358-361. 被引量:2
  • 2Douglas P,Peter Libby,RoberO,et al.心脏病学[M].陈灏珠主译.北京:人民卫生出版社,2007:483-565. 被引量:2
  • 3Pecchia L,Melillo P,Sansone M,et al.Discrimination power of short-termheart rate variability measures for CHF assessment[J].IEEE Transac-tions Inform Technol Biomed,2011;15(1):40-6. 被引量:1
  • 4Schrier RW.Body water homeostasis:clinical disorders of urinary dilution and concentration(J).J Am Soc Nephrol,2006;17(7):1820-32. 被引量:1
  • 5Upanhyay A,Jaber BL,Madiaas NE.Incidence and prevalence of hy-ponatremia(J).Am J Med,2006;119(suppl1):S30-5. 被引量:1
  • 6Hawkins RC.Age and gender as risk factors for hyponatremia and hyper-natremia(J).Clin Chim Acta,2003;337(1-2):169-72. 被引量:1
  • 7Gill G,Huda B,Boyd A,et al.Characteristics and mortality of sever hy-ponatremia-a hospital-based study(J).Clin Endocrinol,2006;65(2):246-9. 被引量:1
  • 8Waikar SS,Mount DB,Curhan GC.Mortality after hospitalization with mild,moderate,and severe hyponatremia(J).Am J Med,2009;122(9):857-65. 被引量:1
  • 9Verbalis JG,Goldsmith SR,Greenberg A,et al.Hyponatremia treatment guidelines 2007:expert panel recommendations(J).Am J Med,2007;120(11A):S1-S21. 被引量:1
  • 10Friedman B,Cirulli J.Hyponatremia in critical care patients:frequency,outcome,characteristics,and treatment with the vasopressin V2-receptor antagonist tolvaptan(J).J Critical Care,2012;8:1-12. 被引量:1

引证文献8

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部